The European Commission has launched a formal antitrust investigation into Sanofi (NASDAQ:SNY) to determine whether the French drugmaker violated EU competition rules through a communication campaign targeting a competing influenza vaccine.
The probe centers on allegations that Sanofi disseminated misleading information about Fluad, an enhanced flu vaccine marketed by CSL Seqirus (OTC:CSLLY), while promoting its own vaccine, Efluelda, in Germany and France.
The latest action follows unannounced inspections conducted at Sanofi’s premises in September 2025.
Benzinga reached out to Sanofi for comment but did not receive a response by the time of publication.
Read Next
